A Phase II Study of Ibrutinib Plus Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma or Elderly Patients With Newly Diagnosed Mantle Cell Lymphoma (MCL)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Feb 2018
At a glance
- Drugs Ibrutinib (Primary) ; Rituximab
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 22 Jan 2018 Planned End Date changed from 1 Jul 2019 to 1 Jul 2020.
- 13 Jun 2017 Planned primary completion date changed from 1 Dec 2019 to 1 Jul 2019.
- 27 Nov 2015 Results published in the Lancet Oncology